What is Leerink Partnrs' Estimate for SPRY FY2029 Earnings?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for ARS Pharmaceuticals in a report released on Sunday, June 22nd. Leerink Partnrs analyst R. Ruiz expects that the company will earn $3.55 per share for the year. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.

Several other equities research analysts have also recently weighed in on SPRY. Wall Street Zen cut shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Scotiabank started coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.00.

ARS Pharmaceuticals Trading Up 0.7%

Shares of SPRY traded up $0.12 during trading hours on Tuesday, hitting $18.20. 3,883,996 shares of the stock were exchanged, compared to its average volume of 1,338,171. ARS Pharmaceuticals has a fifty-two week low of $8.02 and a fifty-two week high of $18.90. The company has a debt-to-equity ratio of 0.30, a current ratio of 11.00 and a quick ratio of 10.74. The business has a 50-day moving average of $14.63 and a 200-day moving average of $13.02. The firm has a market capitalization of $1.79 billion, a P/E ratio of -113.74 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The business had revenue of $7.97 million during the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative net margin of 16.11% and a negative return on equity of 6.94%.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Eric Karas sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $16.00, for a total value of $240,000.00. Following the transaction, the insider now owns 7,696 shares in the company, valued at $123,136. The trade was a 66.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the business's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total value of $1,451,862.90. Following the completion of the transaction, the insider now directly owns 89,613 shares in the company, valued at approximately $1,263,543.30. This represents a 53.47% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 337,971 shares of company stock worth $4,721,888. Insiders own 33.50% of the company's stock.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bernard Wealth Management Corp. purchased a new position in ARS Pharmaceuticals in the fourth quarter valued at about $27,000. ANTIPODES PARTNERS Ltd purchased a new position in ARS Pharmaceuticals in the first quarter valued at approximately $37,000. PNC Financial Services Group Inc. lifted its stake in ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock valued at $49,000 after purchasing an additional 3,905 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in ARS Pharmaceuticals in the fourth quarter valued at approximately $73,000. Finally, BNP Paribas Financial Markets purchased a new position in ARS Pharmaceuticals in the fourth quarter valued at approximately $75,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.